BioDuro established an assay package for STAT6 PROTACs using Kymera I-1 as the primary benchmark for mechanistic characterization, functional activity, selectivity, pharmacodynamics, and disease-model evaluation in atopic dermatitis and asthma.
Public source
Publisher name
Public post
๐ Over 230 million people suffer from atopic dermatitis, yet current therapies face limitations in efficacy and safety. STAT6 PROTACs are being explored as a novel, oraโฆ
Company
BioDuro
Your Global CRDMO, Rooted in Science
- Industry
- Pharmaceutical Manufacturing
- Location
- Irvine, US
- Company size
- 201โ500 employees
About BioDuro
BioDuro, an Advent portfolio company, is a CRDMO with a 30-year proven track record. Headquartered in Irvine, California, BioDuro employs more than 2,000 scientists with deep expertise in small- and large-molecule discovery, development, and manufacturing. We provide fully integrated drug discovery services spanning chemistry, biology, and pharmacokinetics (DMPK), along with comprehensive IND-enabling capabilities, including both drug substance and drug product development. Across 8 sites in mainland China, Taiwan, and the United States. BioDuro supports the innovation needs of clients worldwide. For more information about BioDuro, please visit our website at www.bioduro.com
See moreLatest activity
Latest activity from BioDuro
9 signals
Presence & Recognition
BioDuro is onsite at the EFMC International Symposium on Medicinal Chemistry to present a poster on high-throughput peptide screening for radioligands using DNA-encoded libraries.
Presence & Recognition
BioDuro celebrated Labor Day by thanking colleagues and industry members for their dedication and expertise.
Presence & Recognition
BioDuro is attending the 7th edition of the Fragment-Based Drug Discovery Meeting in Cambridge from September 14-16.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Biocytogen
Biocytogen validated its CRBN humanized mice (B-hCRBN mice) as a platform for evaluating CRBN-dependent protein degradation, pharmacodynamic responses, and safety.
Research & Knowledge
HitChem
HitChem discovered unique and diverse CRBN ligands through in-house research efforts, driving the expansion of the CRBN Molecular Glue Library.
Research & Knowledge
Synovel Laboratory, LLC
Synovel Laboratory, LLC developed molecular-glue-degraders to enhance caprin1 activity.
Research & Knowledge
Enamine Ltd.
Enamine Ltd. proposes broader adoption of the methylated spirocyclic azetidines design strategy for Janus kinase inhibitors, including the FDA-approved drug Deglocitinib.
Research & Knowledge
ChemPartner